Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109863 · ClinicalTrials.gov registry record · Phase 2
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT00109863: Completed Phase 2 study, sponsored by University of Wisconsin, Madison.
NCT00109863 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00109863, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanoma.
Interventions
- BIOLOGICAL hu14.18-IL2 fusion protein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-05 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT00109863 record still lists
NCT00109863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which hu14.18-IL2 fusion protein is the first listed.
NCT00109863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00109863 about?
NCT00109863 is a clinical study titled "Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma". RATIONALE: Biological therapies, such as hu14.18-interleukin-2 fusion protein, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating patients with advanced melanom...
What is the current status of trial NCT00109863?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2005-05. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00109863?
The interventions under investigation include: hu14.18-IL2 fusion protein (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109863?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00109863's enrollment target sits among peer trials
14 1941st of 2000 higher than 54 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia